# RZLT catalysts: Rezolute, Inc. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/rzlt/catalysts

> Rezolute, Inc. (RZLT) has 3 upcoming catalysts. The next is the ersodetug topline data readout, Dec 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, exact day, half-year only, quarter only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | Rezolute, Inc. |
| Ticker | RZLT (Nasdaq) |
| SEC CIK | 1509261 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/rzlt |

## Cash runway

Cash $90.0M as of 2026-09-30; quarterly burn $18.8M; about 14.4 months of runway at that rate (XBRL company facts, accession 0001104659-26-123364).

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Dec 2022 | [RZ402 trial start](https://sec-api.dev/pdufa/rz402) | RZLT |  | completed | "In December 2022, we initiated a Phase 2 multi-center, randomized, double-masked, placebo-controlled, parallel-arm study to evaluate the safety, efficacy, and pharmacokinetics of RZ402 administered as a monotherapy over a twelve week treatment period in participants with DME who are naïve to, or have received limited anti-VEGF injections." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925038086/tm2512716-1_424b5.htm)) |
| December 31, 2024 | [Ersodetug trial start](https://sec-api.dev/pdufa/ersodetug) | RZLT |  | completed | "For the three months ended December 31, 2024, there were de minimis clinical costs incurred for tumor HI related program spend as the Phase 3 upLIFT study had yet to be initiated and clinical costs for the Phase 3 sunRIZE study were lower as we did not complete enrollment of patients until May 2025." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1509261/000110465926014334/rzlt-20251231x10q.htm)) |
| 1H 2025 | [Ersodetug topline data readout](https://sec-api.dev/pdufa/ersodetug) | RZLT |  | scheduled | "Topline results from the study are anticipated to be available in the first half of 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925038086/tm2512716-1_424b5.htm)) |
| February 12, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "(Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage biopharmaceutical company dedicated to developing transformative therapies for rare diseases with serious unmet needs, today reported financial results and provided a business update for the three months ended December 31, 2024." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925012173/tm255593d1_ex99-1.htm)) |
| Q2 2025 | [Ersodetug trial start](https://sec-api.dev/pdufa/ersodetug) | RZLT | hypoglycemia due to tumor HI, and patient enrollment | scheduled | "We are initiating start-up activities for a Phase 3 registrational study of ersodetug for the treatment of hypoglycemia due to tumor HI, and patient enrollment is planned to commence in the second quarter of 2025." ([SEC prospectus (424B)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925038086/tm2512716-1_424b5.htm)) |
| April 23, 2025 | [Rezolute, Inc. interim data readout](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed, positive | "On April 23, 2025, we announced a positive outcome from an interim analysis of the sunRIZE study." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1509261/000155837025007582/rzlt-20250331x10q.htm)) |
| May 13, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "(Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended March 31," ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925047832/tm2514822d1_ex99-1.htm)) |
| September 17, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "CITY, Calif., September 17, 2025 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925090834/tm2526049d1_ex99-1.htm)) |
| November 6, 2025 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "- Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today reported financial results and provided a business update for the three months ended September 30, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925107743/tm2529989d1_ex99-1.htm)) |
| Dec 2025 | [Rezolute, Inc. topline data readout](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | scheduled | "Eligible participants may continue in a long - term extension study following pivotal treatment o Topline results expected December 2025 \| 12 Phase 3: The sunRIZE Study SOC: standard of care." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/tm2524786d1_ex99-2.htm)) |
| Dec 2025 | [Ersodetug topline data readout](https://sec-api.dev/pdufa/ersodetug) | RZLT | congenital HI | completed, missed | "FDA also confirmed that Rezolute's pivotal sunRIZE trial in congenital HI, which is on track to report topline results in December 2025, would serve as confirmatory clinical evidence, and is demonstrative of FDA's recognition of the broad applicability of ersodetug in multiple forms of HI." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465925085892/tm2524786d1_ex99-1.htm)) |
| Dec 2025 | [Rezolute, Inc. topline data readout](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | scheduled | "Topline results from the study are anticipated to be available in December 2025, but the specific date of the availability of such results may vary." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1509261/000110465925107781/rzlt-20250930x10q.htm)) |
| February 12, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "CITY, Calif., February 12, 2026 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of hyperinsulinism (HI), today reported financial results and provided a business update for the three months ended December 31, 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926014287/tm265567d1_ex99-1.htm)) |
| May 12, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926059392/tm2614169d1_ex99-1.htm)) |
| Jun 2026 | [Ersodetug interim data readout](https://sec-api.dev/pdufa/ersodetug) | RZLT |  | completed, positive | "June 2026, the Company shared positive interim data from the upLIFT study, announcing that of the 8 participants enrolled, 6 had already met the responder criterion for the study's primary endpoint within the 8-week pivotal treatment phase." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_ex99-1.htm)) |
| late 2026 | [Rezolute, Inc. topline data readout](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | scheduled | "Topline results from the study are anticipated to be available in the second half of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1509261/000110465925090848/rzlt-20250630x10k.htm)) |
| September 24, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "Calif., September 24, 2026 - Rezolute, Inc. (Nasdaq: RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare rare disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the fourth quarter and full fiscal year ended June 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926110412/tm2625842d1_ex99-1.htm)) |
| November 5, 2026 | [Rezolute, Inc. earnings report](https://sec-api.dev/companies/rzlt/catalysts) | RZLT |  | completed | "CITY, Calif., November 5, 2026 - Rezolute, Inc. (Nasdaq: RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any form of hyperinsulinism (HI), today reported financial results and provided a business update for the first quarter ended September 30, 2026." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926123336/tm2628931d2_ex99-1.htm)) |
| Dec 2026 | [Ersodetug topline data readout](https://sec-api.dev/pdufa/ersodetug) | RZLT | hypoglycemia caused | scheduled | "Topline results expected mid - December 2026" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926120205/tm2628517d1_ex99-1.htm)) |
| 2027 | [Ersodetug topline data readout](https://sec-api.dev/pdufa/ersodetug) | RZLT |  | scheduled | ""Now that we have a path forward for congenital hyperinsulinism, we look forward to announcing topline data from upLIFT and to the extent the study outcomes are favorable, the potential to advance both indications in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926115874/tm2627620d1_ex99-1.htm)) |
| 2027 | [Ersodetug NDA/BLA submission](https://sec-api.dev/pdufa/ersodetug) | RZLT |  | scheduled | "Company's plans and expectations regarding a pre-BLA meeting and the potential submission of one or two Biologics License Applications (BLA) for ersodetug for both of tumor HI and congenital HI in 2027; the potential safety, efficacy and therapeutic potential of ersodetug for treating refractory hypoglycemia caused by any form of HI." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1509261/000110465926126502/tm2627558d10_ex99-1.htm)) |

## Drugs

- [Ersodetug](https://sec-api.dev/pdufa/ersodetug): hypoglycemia due to tumor hi, and patient enrollment, hypoglycemia caused, congenital hi
- [RZ402](https://sec-api.dev/pdufa/rz402): 

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/rzlt/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "RZLT catalysts: Rezolute, Inc. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/rzlt/catalysts

```bibtex
@misc{secapidev_companies_rzlt_catalysts_20261116,
  title        = {RZLT catalysts: Rezolute, Inc. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/rzlt/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_rzlt_catalysts_20261116","title":"RZLT catalysts: Rezolute, Inc. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/rzlt/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
